$68.13
0.03% day before yesterday
Nasdaq, Nov 28, 09:50 pm CET
ISIN
US23282W6057
Symbol
CYTK

Cytokinetics, Incorporated Stock price

$68.13
+6.16 9.94% 1M
+37.85 125.00% 6M
+21.09 44.83% YTD
+15.91 30.47% 1Y
+28.04 69.94% 3Y
+51.33 305.54% 5Y
+56.31 476.40% 10Y
+15.81 30.22% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
-0.02 0.03%

Key metrics

Basic
Market capitalization
$8.3b
Enterprise Value
$8.4b
Net debt
$103.0m
Cash
$962.5m
Shares outstanding
122.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
95.5 | 97.3
EV/Sales
96.7 | 98.5
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-9.7%
Return on Equity
435.5%
ROCE
-44.3%
ROIC
-
Debt/Equity
-2.0
Financials (TTM | estimate)
Revenue
$87.2m | $85.6m
EBITDA
$-563.3m | $-630.8m
EBIT
$-572.9m | $-639.6m
Net Income
$-751.9m | $-700.1m
Free Cash Flow
$-453.8m
Growth (TTM | estimate)
Revenue
2,608.4% | 363.7%
EBITDA
-10.2% | -19.8%
EBIT
-9.2% | -19.3%
Net Income
-30.4% | -18.8%
Free Cash Flow
-11.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-645.9% | -736.5%
EBIT
-656.9%
Net
-862.2% | -817.4%
Free Cash Flow
-520.4%
More
EPS
$-6.3
FCF per Share
$-3.7
Short interest
15.2%
Employees
498
Rev per Employee
$40.0k
Show more

Is Cytokinetics, Incorporated a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Cytokinetics, Incorporated Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Cytokinetics, Incorporated forecast:

21x Buy
81%
5x Hold
19%

Analyst Opinions

26 Analysts have issued a Cytokinetics, Incorporated forecast:

Buy
81%
Hold
19%

Financial data from Cytokinetics, Incorporated

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
87 87
2,608% 2,608%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 255 255
29% 29%
292%
- Research and Development Expense 405 405
23% 23%
465%
-563 -563
10% 10%
-646%
- Depreciation and Amortization 9.64 9.64
28% 28%
11%
EBIT (Operating Income) EBIT -573 -573
9% 9%
-657%
Net Profit -752 -752
30% 30%
-862%

In millions USD.

Don't miss a Thing! We will send you all news about Cytokinetics, Incorporated directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cytokinetics, Incorporated Stock News

Positive
Seeking Alpha
10 days ago
Cytokinetics is positioned as a precision cardiac mechanics platform leader, with aficamten as the first proof-of-concept and multiple pipeline assets. Aficamten's differentiated REMS, rapid titration, and superior safety could disrupt the cardiac myosin inhibitor market, expanding prescriber adoption and accelerating patient switching from competitors. CYTK's robust cash position, efficient co...
Neutral
GlobeNewsWire
11 days ago
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 15, 2025 it granted stock options to purchase 87,297 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to Jeffrey Hessekiel, the Company's Executive Vice President, Chief Legal and Administrative Officer, whose employme...
Neutral
PRNewsWire
12 days ago
NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and May 6, 2025, both dates inclusive (the "Class Period"), of the important November 17, 2025 lead plaintiff deadline. So what: If you purchased Cytokinetics common stock during the Class Period you ma...
More Cytokinetics, Incorporated News

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Head office United States
CEO Robert Blum
Employees 498
Founded 1997
Website cytokinetics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today